Soligenix (NASDAQ:SNGX) Issues Earnings Results

Soligenix (NASDAQ:SNGX) posted its earnings results on Friday. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.19), Zacks reports. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. During the same period in the prior year, the firm earned ($12.66) earnings per share.

Soligenix Trading Up 0.4 %

Shares of NASDAQ:SNGX opened at $2.39 on Friday. The stock has a market capitalization of $6.00 million, a PE ratio of -0.32 and a beta of 2.03. Soligenix has a 1 year low of $1.83 and a 1 year high of $14.92. The firm has a fifty day moving average price of $2.37 and a 200 day moving average price of $3.12.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.